Turner Investments adds Edwards Lifesciences Corp (EW) to its portfolio

Edwards Lifesciences Corp (EW) : Turner Investments added new position in Edwards Lifesciences Corp during the most recent quarter end. The investment management firm now holds 55,150 shares of Edwards Lifesciences Corp which is valued at $5.7 Million , the company said in a statement filed on May 13, 2016 with the SEC.Edwards Lifesciences Corp makes up approximately 1.57% of Turner Investments’s portfolio.

Other Hedge Funds, Including , Burnham Asset Management Corp Ny reduced its stake in EW by selling 470 shares or 1.12% in the most recent quarter. The Hedge Fund company now holds 41,650 shares of EW which is valued at $4.3 Million. Edwards Lifesciences Corp makes up approx 1.36% of Burnham Asset Management Corp Ny’s portfolio.Smith Asset Management Group Lp reduced its stake in EW by selling 83,580 shares or 13.69% in the most recent quarter. The Hedge Fund company now holds 527,070 shares of EW which is valued at $55.7 Million. Edwards Lifesciences Corp makes up approx 1.68% of Smith Asset Management Group Lp’s portfolio.Ifp Advisors Inc boosted its stake in EW in the latest quarter, The investment management firm added 1,006 additional shares and now holds a total of 10,308 shares of Edwards Lifesciences Corp which is valued at $1.1 Million. Edwards Lifesciences Corp makes up approx 0.07% of Ifp Advisors Inc’s portfolio.Tokio Marine Asset Management Co Ltd boosted its stake in EW in the latest quarter, The investment management firm added 932 additional shares and now holds a total of 7,572 shares of Edwards Lifesciences Corp which is valued at $800,663. Edwards Lifesciences Corp makes up approx 0.08% of Tokio Marine Asset Management Co Ltd’s portfolio.

Edwards Lifesciences Corp closed down -1.58 points or -1.56% at $99.91 with 15,25,779 shares getting traded on Wednesday. Post opening the session at $101.79, the shares hit an intraday low of $99.69 and an intraday high of $101.96 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Edwards Lifesciences Corp reported $0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.66. The company had revenue of $697.30 million for the quarter, compared to analysts expectations of $666.93 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.

Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Company shares were Reiterated by Canaccord Genuity on May 23, 2016 to “Buy”, Firm has raised the Price Target to $ 132 from a previous price target of $123 .Company shares were Reiterated by RBC Capital Mkts on Apr 27, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $110 .Company shares were Reiterated by Canaccord Genuity on Apr 27, 2016 to “Buy”, Firm has raised the Price Target to $ 123 from a previous price target of $113 .

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.

Leave a Reply

Edwards Lifesciences Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Edwards Lifesciences Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.